Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman,Rebecca Paulus,James M. Galvin,Jeff M. Michalski,William L. Straube,Jeffrey D. Bradley,Achilles J. Fakiris,Andrea Bezjak,Gregory M.M. Videtic,David W. Johnstone,Jack F. Fowler,Elizabeth Gore,Hak Choy +12 more
Reads0
Chats0
TLDR
Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.Abstract:
Context Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management. Objective To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. Design, Setting, and Patients Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non–small cell tumors (measuring Main Outcome Measures The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. Results A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6% (95% confidence interval [CI], 84.3%-99.7%). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6% (95% CI, 76.0%-96.5%). Two patients experienced regional failure; the local-regional control rate was 87.2% (95% CI, 71.0%-94.7%). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1% (95% CI, 12.3%-37.8%). The rates for disease-free survival and overall survival at 3 years were 48.3% (95% CI, 34.4%-60.8%) and 55.8% (95% CI, 41.6%-67.9%), respectively. The median overall survival was 48.1 months (95% CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade 4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7%-4.5%). No grade 5 adverse events were reported. Conclusion Patients with inoperable non–small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.read more
Citations
More filters
Journal ArticleDOI
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch,Giorgio V. Scagliotti,James L. Mulshine,Regina Kwon,Walter J. Curran,Yi-Long Wu,Luis Paz-Ares +6 more
TL;DR: Prevention and early detection of lung cancer with an emphasis on lung cancer screening is discussed, and the importance of smoking prevention and cessation is acknowledged.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
TL;DR: Surgical resection remains the primary and preferred approach to the treatment of stage I and II NSCLC, and mediastinal lymph node sampling at the time of curative intent surgical resection can be performed without increased morbidity.
Journal ArticleDOI
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more
TL;DR: Overall survival for SABR versus surgery by pooling data from the STARS and ROSEL trials was 95% (95% CI 85-100) in the S ABR group compared with 79% in the surgery group, and recurrence-free survival at 3 years was 86% ( 95% CI 74-100).
Journal ArticleDOI
Non-small cell lung cancer: current treatment and future advances
Cecilia Zappa,Shaker A. Mousa +1 more
TL;DR: Current treatments including surgery, chemotherapy, radiotherapy, and immunotherapy are discussed as well as how biomarker testing has helped improve survival in patients with NSCLC.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer
Robert Timmerman,Ronald C. McGarry,Constantin T. Yiannoutsos,Lech Papiez,Kathy Tudor,Jill DeLuca,Marvene Ewing,Ramzi Abdulrahman,Colleen DesRosiers,Mark J. Williams,James W. Fletcher +10 more
TL;DR: High rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC, and this regimen should not be used for patients with tumors near the central airways due to excessive toxicity.
Journal ArticleDOI
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
TL;DR: A one-sample multiple testing procedure is proposed which employs the standard single-stage test procedure at the last test, and which both allows for early termination and essentially preserves the size, power and simplicity of the single- stage procedure.
Related Papers (5)
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more